Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and its Croatian subsidiary, Pliva, opened a new tablets and capsules manufacturing plant in Zagreb on Friday, at an investment of $100 million. Pliva has hired 200 new employees. Pliva CEO Tihomir Oreskovic said that the plant would expand the company’s production capacity. The company’s output is exported worldwide.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
The new plant will increase Pliva’s production capacity by 25% to two billion tablets and capsules a year. Production will begin as soon as the plant obtains US Food and Drug Administration (FDA) and European Medicines Agency (EMEA) certification.
Published by www.globes-online.com